Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURVASCC: Durvalumab in ES-EPSCC
NCT06464068Phase 2Recruiting
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jan 2024
- Primary completion
- Jan 2028
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in extrapulmonary small cell carcinoma (EPSCC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Started Jan 2024; status: recruiting.
02
Drugs
durvalumab
03
Conditions
extrapulmonary small cell carcinoma (EPSCC)
Beyond the preview
Go deeper on NCT06464068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06464068.